Microneedles: A novel clinical technology for evaluating skin characteristics

字号 + –

04 12月 2024

1
2
3
4
5

Author : 伤口世界

Microneedles: A novel clinical technology for evaluating skin characteristics

Seo Hyeong Kim1 Ji Hye Kim1 Yoon Mi Choi1 Su Min Seo1 Eun Young Jang1 Sung Jae Lee1 Suhyun Cho2 Do Hyeon Jeong3 Kwang Hoon Lee1

1 Cutis Biomedical Research Center Co. Ltd., Seoul, Republic of Korea

2 Yonsei BB Skin Clinic, Seoul, Republic of Korea

3 Raphas Co. Ltd., Seoul, Republic of Korea

Correspondence

Kwang Hoon Lee, Cutis Biomedical Research Center Co. Ltd., (07327) 5F, 97, Uisadang-daero, Yeongdeungpo-gu, Seoul, Republic of Korea.

Email: 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。

Abstract

Background: Current methods for evaluating efficacy of cosmetics have limitations because they cannot accurately measure changes in the dermis. Skin sampling using microneedles allows identification of skin-type biomarkers, monitoring treatment for skin inflammatory diseases, and evaluating efficacy of anti-aging and anti-pigmentation products.

Materials and methods: Two studies were conducted: First, 20 participants received anti-aging treatment; second, 20 participants received anti-pigmentation treatment. Non-invasive devices measured skin aging (using high-resolution 3D-imaging in the anti-aging study) or pigmentation (using spectrophotometry in the anti-pigmentation study) at weeks 0 and 4, and adverse skin reactions were monitored. Skin samples were collected with biocompatible microneedle patches. Changes in expression of biomarkers for skin aging and pigmentation were analyzed using qRT-PCR.

Results: No adverse events were reported. In the anti-aging study, after 4 weeks, skin roughness significantly improved in 17 out of 20 participants. qRT-PCR showed significantly increased expression of skin-aging related biomarkers: PINK1 in 16/20 participants, COL1A1 in 17/20 participants, and MSN in 16/20 participants. In the anti-pigmentation study, after 4 weeks, skin lightness significantly improved in 16/20 participants. qRT-PCR showed significantly increased expression of skinpigmentation-related biomarkers: SOD1 in 15/20 participants and Vitamin D Receptor (VDR) in 15/20 participants. No significant change in TFAP2A was observed.

Conclusion: Skin sampling and mRNA analysis for biomarkers provides a novel, objective, quantitative method for measuring changes in the dermis and evaluating the efficacy of cosmetics. This approach complements existing evaluation methods and has potential application in assessing the effectiveness of medical devices, medications, cosmeceuticals, healthy foods, and beauty devices.

KEYWORDS

in vivo efficacy test, skin aging, skin biomarkers, skin pigmentation

This article is excerpted from the Skin Res Technol. 2024;30:e13647 by Wound World.

15 Views

伤口世界

电子邮件地址该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。

Latest from 伤口世界

K2 Content

Microneedles: A novel clinical technology for evaluating skin characteristics 2024-12-04 00:00

Seo Hyeong Kim1 Ji Hye Kim1 Yoon Mi Choi1 Su Min Seo1 Eun Young Jang1 Sung Jae Lee1 Suhyun Cho2 Do Hyeon Jeong3 Kwang Hoon Lee1

1 Cutis Biomedical Research Center Co. Ltd., Seoul, Republic of Korea

2 Yonsei BB Skin Clinic, Seoul, Republic of Korea

3 Raphas Co. Ltd., Seoul, Republic of Korea

Correspondence

Kwang Hoon Lee, Cutis Biomedical Research Center Co. Ltd., (07327) 5F, 97, Uisadang-daero, Yeongdeungpo-gu, Seoul, Republic of Korea.

Email: 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。

Abstract

Background: Current methods for evaluating efficacy of cosmetics have limitations because they cannot accurately measure changes in the dermis. Skin sampling using microneedles allows identification of skin-type biomarkers, monitoring treatment for skin inflammatory diseases, and evaluating efficacy of anti-aging and anti-pigmentation products.

Materials and methods: Two studies were conducted: First, 20 participants received anti-aging treatment; second, 20 participants received anti-pigmentation treatment. Non-invasive devices measured skin aging (using high-resolution 3D-imaging in the anti-aging study) or pigmentation (using spectrophotometry in the anti-pigmentation study) at weeks 0 and 4, and adverse skin reactions were monitored. Skin samples were collected with biocompatible microneedle patches. Changes in expression of biomarkers for skin aging and pigmentation were analyzed using qRT-PCR.

Results: No adverse events were reported. In the anti-aging study, after 4 weeks, skin roughness significantly improved in 17 out of 20 participants. qRT-PCR showed significantly increased expression of skin-aging related biomarkers: PINK1 in 16/20 participants, COL1A1 in 17/20 participants, and MSN in 16/20 participants. In the anti-pigmentation study, after 4 weeks, skin lightness significantly improved in 16/20 participants. qRT-PCR showed significantly increased expression of skinpigmentation-related biomarkers: SOD1 in 15/20 participants and Vitamin D Receptor (VDR) in 15/20 participants. No significant change in TFAP2A was observed.

Conclusion: Skin sampling and mRNA analysis for biomarkers provides a novel, objective, quantitative method for measuring changes in the dermis and evaluating the efficacy of cosmetics. This approach complements existing evaluation methods and has potential application in assessing the effectiveness of medical devices, medications, cosmeceuticals, healthy foods, and beauty devices.

KEYWORDS

in vivo efficacy test, skin aging, skin biomarkers, skin pigmentation
Is Acne the Same Around the World? 2024-12-03 00:00

by ANDREW ALEXIS, MD, MPH; JERRY TAN, MD; MARCO ROCHA, MD, PhD; DELPHINE KEROB, MD; ANN’LAURE DEMESSANT, PharmD; FATIMATA LY MD; YAN WU, MD, PhD; MUKTA SACHDEV, MD; and ICHIRO KUROKAWA, MD, PhD

Dr. Alexis is with the Department of Dermatology, Weill Cornell Medicine, New York, New York. Dr. Tan is with Western University, Windsor in Ontario, Canada. Dr. Rocha is with the Department

of Dermatology, Federal University of São Paulo in São Paulo, Brazil. Drs. Kerob and Demessant are with La Roche-Posay Laboratoire Dermatological Beauty in Paris, France. Dr. Ly is with the

Dermatology Department at the University Cheikh Anta Diop of Dakar in Dakar, Senegal, West Africa. Dr. Wu is with the Department of Dermatology, Peking University First Hospital in Beijing, China. Dr. Sachdev is with the Department of Dermatology, Manipal Hospital in Bangalore, India. Dr. Kurokawa is with the Department of Dermatology at the Meiwa Hospital in Hyogo, Japan.

J Clin Aesthet Dermatol. 2024;17(9):16–22.

Acne is a common skin disease associated with a range of sequelae. These include scarring and dyspigmentation, emotional and psychosocial disturbances, and occupational problems, in part because acne often manifests on the face, in addition to other body areas, and is highly visible. Worldwide, the prevalence of acne is estimated at 9.4 percent; it is most common in adolescents but also affects a relatively high proportion of adults. Early studies of acne epidemiology were conducted primarily in the United States and the United Kingdom. In more recent decades, data have been increasing for other areas of the world. There has also been more attention devoted to how acne may present and be managed in individuals with skin of color (i.e., the broad and diverse range of populations that self-identify as belonging to a non-White racial/ethnic group and share characteristics such as higher skin phototypes and propensity toward hyperpigmentation). This review seeks to highlight aspects of acne that may be unique to skin of color.

KEYWORDS: Acne vulgaris, skin of color, ethnicity, race

FUNDING: Funding for this study was provided by La Roche-Posay.

DISCLOSURES: Dr Alexis has served as a consultant and/or advisory board member for Leo, Novartis, Galderma Laboratories LP, Sano Regeneron, Dermavant, Unilever, Beiersdorf, Valeant, L’Oreal, Bristol Meyers Squibb, Scientis, Bausch Health, UCB, Arcutis, Janssen, Allergan, Almirall, AbbVie, and Sol-Gel. Dr Tan has received grants, honoraria, or served as a consultant for Bausch, Boots Walgreens, Cipher, Cutera, Galderma, La Roche Posay, Novartis, Pierre Fabre, and P zer. Dr Rocha has served as an advisor and/or received honoraria from Galderma, Pierre-Fabre, Eucerin, La Roche Posay, and Leo Pharma. Dr Kerob and Dr Demessant are employees of L’Oreal. Dr Ly has served as consultant and received honoraria from La Roche Posay. Pr Wu and Dr Sachdev have served consultants for L’Oreal. Dr. Kurokawa has received research grants from Aisin Corporation and served as a consultant for L’Oreal.

CORRESPONDENCE: Delphine Kerob, MD; Email: 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
Infraorbital Rejuvenation Combined with Thread-Lifting and Non-cross-linked Hyaluronic Acid Injection: A Retrospective, Case-Series Study 2024-12-02 00:00

Zhi-Feng Liao1 • Wei Yang2 • Xin Li3 •Shi-wei Wang3 • Fang-Cen Liu4 • Sheng-Kang Luo1

1 Department of Plastic and Reconstructive Surgery, Guangdong Second Provincial General Hospital, 466 Middle Xin Gang Road, Guangzhou City 510317, Guangdong Province, China

2 Department of Medical Cosmetology, Beijing Huaxia Medical Beauty Hospital, Beijing, China

3 Department of Medical, Imeik Technology Development Co., Ltd., Beijing, China

4 Guangzhou Yestar Medical Aesthetic Hospital, Guangzhou City, Guangdong Province, China

Received: 3 August 2023 / Accepted: 20 October 2023 / Published online: 14 November 2023 © The Author(s) 2023

Abstract

Background Infraorbital aging develops during the natural aging process. Various treatment options offer unique benefits, accompanied by diverse side effect profiles, and can be synergistically combined to optimize results. This study aimed to evaluate the efficacy of a comprehensive approach involving non-cross-linked hyaluronic acid injection and smooth absorbable PPDO (poly p-dioxanone) thread insertion for infraorbital rejuvenation.

Methods This retrospective case series study enrolled ten female patients with infraorbital aging from March 2022 to April 2023. Clinical outcomes, patient satisfaction, and adverse events were assessed at 1, 3, and 6 months

Results The median Global Aesthetic Improvement Scale scores evaluated by the operator and blinded evaluator were 1.70 ± 0.42 and 1.80 ± 0.35, respectively, at six months posttreatment. The median Allergan Infraorbital

Hollows Scale determined by the operator was 1.15 ± 0.34 at six months posttreatment, whereas the scores evaluated by the blinded evaluator were 1.15 ± 0.53. At six months after treatment, 50% of patients were satisfied, and an additional 40% reported strong satisfaction with the clinical improvement following treatment. No serious adverse events, such as infections, lumps, irregularities, Tyndall effect, hematoma, or skin necrosis, occurred during the treatment period.

Conclusions The combination of PPDO thread insertion and non-cross-linked hyaluronic acid injection yielded satisfactory and effective clinical outcomes with no occurrence of serious adverse events for infraorbital rejuvenation. We anticipate that this study will contribute to the advancement of novel treatment options for infraorbital aging.

Level of Evidence IV

This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.

Keywords Infraorbital rejuvenation Hyaluronic acid injections Thread-lifting Infraorbital aging

Custom Mod Mega1

主任医师、教授、博导，南方医科大学第三附属医院（广东省骨科医院）院长